Skip to content

Abnormal Uterine Bleeding Management

An Open Label Clinical Study to Evaluate the efficacy of Menohelp in Asrigdara W.S.R. to Abnormal Uterine Bleeding (AUB)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/12/038921
Enrollment
200
Registered
2021-12-24
Start date
Unknown
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N939- Abnormal uterine and vaginal bleeding, unspecified

Interventions

None listed

Sponsors

Magnet Labs under Mankind Pharma
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Women of reproductive age group 18-45 years. 2. Excessive bleeding during menstruation (menstrual blood loss > 80 ml in 1-7 days) or having Pictorial blood loss assessment chart (PBLAC) score more than 100 points for 2 consecutive cycles. 3. Prolonged menstrual bleeding (With the duration of bleeding >7 days) Inter menstrual bleeding 4. Frequent menstrual cycle (interval 5. Patients who are willing to go for relevant investigation 6. Normal gynaecological examination and PAP smear

Exclusion criteria

Exclusion criteria: • Patients with any diagnosed uterine organic pathology like Adenomyosis, and chronic tubo ovarian mass. • Submucosal or intramural fibroids, or subcervical fibroids greater than 3cm. • Patients with systemic diseases like hypertension, diabetic mellitus, congestive cardiac failure etc. • Patients with coagulopathy, liver and thyroid dysfunction etc. • Patient with malignancy or undiagnosed neoplasm. • Patients with history of recent abortion. • Patients with active genital tuberculosis. • Bleeding from the polyps and erosion. • IUCD in utero, pelvic endometriosis. • Hb

Design outcomes

Primary

MeasureTime frame
Changes in the clinical features of AUB i.e. Mean reduction from baseline in the amount of uterine bleeding evaluated by PBLAC (Pictorial Blood Loss Assessment Chart) at 30 days, day 60 and day 90 Changes in the duration of bleeding. Attainment of normal interval of menstrual cycles Changes in Quality of life and treatment induced changes in menstrual blood loss (MBL) through Menorrhagia Impact Questionnaire Timepoint: 1. Baseline 2. After each menstrual cycle during treatment 3. After each menstrual cycle in folloe up

Secondary

MeasureTime frame
â?¢ Safety and efficacy of Menohelp in AUB â?¢ Pain during menstruation Timepoint: follow up period

Countries

India

Contacts

Public ContactDr Kamini Dhiman

AlIA New Delhi

drkaminidhiman@outlook.com08920900968

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026